REVOLUTION MEDICINES INC. - COMMON STOCK

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

09 апр 2024 14:34:07 Источник Nasdaq GlobeNewswire

Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

08 апр 2024 10:36:55 Источник Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

04 апр 2024 15:05:04 Источник Nasdaq GlobeNewswire

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

28 мар 2024 15:05:40 Источник Nasdaq GlobeNewswire

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

26 фев 2024 15:05:50 Источник Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024

20 фев 2024 15:05:47 Источник Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

01 фев 2024 15:05:00 Источник Nasdaq GlobeNewswire

Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference

04 янв 2024 06:00:08 Источник Nasdaq GlobeNewswire

Revolution Medicines Completes Acquisition of EQRx

09 ноя 2023 08:10:58 Источник Nasdaq GlobeNewswire

Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition

08 ноя 2023 10:30:46 Источник Nasdaq GlobeNewswire

Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress

06 ноя 2023 15:05:18 Источник Nasdaq GlobeNewswire

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.

01 ноя 2023 06:00:00 Источник Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023

31 окт 2023 15:15:00 Источник Nasdaq GlobeNewswire

Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236

22 окт 2023 01:30:28 Источник Nasdaq GlobeNewswire

Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting

13 окт 2023 10:50:29 Источник Nasdaq GlobeNewswire

Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast

04 окт 2023 15:05:07 Источник Nasdaq GlobeNewswire

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor

19 сен 2023 06:00:38 Источник Nasdaq GlobeNewswire

Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins

17 авг 2023 15:05:58 Источник Nasdaq GlobeNewswire

Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress

08 авг 2023 15:05:04 Источник Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023

03 авг 2023 15:05:54 Источник Nasdaq GlobeNewswire